CAT

914.62

+1.13%↑

322.19

-1.82%↓

GEV.US

930.4

-0.42%↓

RTX

178.55

-1.33%↓

215.74

+0.08%↑

CAT

914.62

+1.13%↑

322.19

-1.82%↓

GEV.US

930.4

-0.42%↓

RTX

178.55

-1.33%↓

215.74

+0.08%↑

CAT

914.62

+1.13%↑

322.19

-1.82%↓

GEV.US

930.4

-0.42%↓

RTX

178.55

-1.33%↓

215.74

+0.08%↑

CAT

914.62

+1.13%↑

322.19

-1.82%↓

GEV.US

930.4

-0.42%↓

RTX

178.55

-1.33%↓

215.74

+0.08%↑

CAT

914.62

+1.13%↑

322.19

-1.82%↓

GEV.US

930.4

-0.42%↓

RTX

178.55

-1.33%↓

215.74

+0.08%↑

Inicio・Lista de Acciones・Ocugen Inc

Ocugen Inc

Cerrado

1.25 -2.34

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.25

Máximo

1.3

Métricas clave
By Trading Economics
Ingresos	-1.5M -19M
Ventas	1.7M 1.5M
BPA	-0.06
Margen de beneficios	-1,250.946
Empleados	116
EBITDA	-987K -17M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+807.14% upside

Dividendos
By Dow Jones
Próximas Ganancias	31 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-162M 464M
Apertura anterior	3.59
Cierre anterior	1.25

Ocugen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 jun 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 jun 2026, 15:41 UTC

Principales Movimientos del Mercado

American Battery Shares Jump on Energy Department Victory

8 jun 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 jun 2026, 23:37 UTC

Charlas de Mercado

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 jun 2026, 23:25 UTC

Charlas de Mercado

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 jun 2026, 23:25 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 jun 2026, 21:57 UTC

Adquisiciones, fusiones, absorciones

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 jun 2026, 21:56 UTC

Adquisiciones, fusiones, absorciones

Salesforce Agrees to Buy m3ter

8 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

8 jun 2026, 19:22 UTC

Charlas de Mercado

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 jun 2026, 19:01 UTC

Charlas de Mercado

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 jun 2026, 18:52 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

8 jun 2026, 18:52 UTC

Charlas de Mercado

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 jun 2026, 18:17 UTC

Charlas de Mercado

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 jun 2026, 17:32 UTC

Charlas de Mercado

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 jun 2026, 17:29 UTC

Charlas de Mercado

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 jun 2026, 17:29 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 jun 2026, 16:55 UTC

Adquisiciones, fusiones, absorciones

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 jun 2026, 16:54 UTC

Adquisiciones, fusiones, absorciones

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 jun 2026, 16:40 UTC

Charlas de Mercado

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 jun 2026, 16:31 UTC

Charlas de Mercado

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 jun 2026, 16:27 UTC

Charlas de Mercado

Mexican Inflation Seen Easing in May -- Market Talk

8 jun 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 jun 2026, 16:03 UTC

Adquisiciones, fusiones, absorciones

Orange Bought Stake From Lorca

8 jun 2026, 16:01 UTC

Adquisiciones, fusiones, absorciones

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 jun 2026, 16:01 UTC

Adquisiciones, fusiones, absorciones

Orange Acquires 100% Ownership of MasOrange

8 jun 2026, 15:58 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 jun 2026, 15:58 UTC

Charlas de Mercado

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 jun 2026, 15:55 UTC

Charlas de Mercado

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 jun 2026, 15:41 UTC

Charlas de Mercado

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparación entre iguales

Cambio de precio

Ocugen Inc previsión

Precio Objetivo

By TipRanks

807.14% repunte

Estimación a 12 Meses

Media 11.43 USD 807.14%

Máximo 22 USD

Mínimo 7 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Ocugen Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.